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gologic diseases marketed in Japan. Contact dermatitis (CD) is one of well-known 
adverse events provoked by fradiomycin sulfate. The objectives of this study were to 
investigate the incidence of CD after the prescription of topical drugs containing fra-
diomycin in clinical practice and to assess background characteristics of the patients 
who were diagnosed CD by using Japanese health care database (HDB). Methods: 
The data were extracted from Japanese HDB (MinaCare Co. Ltd) which contained 
data from people covered by employment-based insurances as of April 2013. We 
classified the patients into three groups with prescription of F/M, fradiomycin sul-
fate - betamethasone sodium phosphate combination ointment (F/B, comparable 
to F/M) or betamethasone sodium phosphate solution (B, as a negative control), 
respectively. The ICD-10 classification was used to identify CD required medication 
after the prescription. Background characteristics of the patients who were diag-
nosed CD after the prescription was also investigated. Results: Out of 1,223,905 
patients (male: 531,030, female: 692,875), we have identified the F/M group (20,702 
patients), the F/B group (5,540 patients) and the B group (108,810 patients). In the F/M 
group, CD which was suspected causal relationship with the drug was detected in 
around 0.25% of patients according to the chronological order of the prescription and 
diagnosis in claim database. Similar tendency was observed in the F/B group, while 
lower incidence of CD was observed in the B group. ConClusions: We utilized 
MinaCare HDB to assess the incidence of CD required medication after topical drugs 
prescription in real clinical settings. CD was detected at higher incidence with the 
drugs containing fradiomycin than steroid alone. While further analysis is needed 
for more accuracy, our approach designed to diminish limitations’ influences was 
useful to assess risk and benefit of drugs.
SenSory SyStemS DiSorDerS – Cost Studies
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objeCtives: sVMA is a serious, sight-threatening and progressive condition which, 
if untreated, leads to irreversible retinal damage, vision loss, and reduced visual 
function. Current standard of care for sVMA is vitrectomy, which has a high rate 
of complications and requires patients to maintain a “head-down” position for up 
to two weeks, resulting in additional surgical costs, discomfort and significant car-
egiver burden. Ocriplasmin (Jetrea®), a single intravitreal injection to resolve sVMA, 
was recently approved in the UK and US. A budget impact analysis was performed 
to test the hypothesis that ocriplasmin can provide cost savings to a hypothetical 
managed care plan by reducing total vitrectomies to resolve sVMA. Methods: 
An Excel-based economic model was designed from the perspective of a managed 
care plan to quantify total direct costs of treating patients with sVMA across two 
scenarios: 1) the current treatment paradigm, consisting of clinical management 
or vitrectomy, and 2) future treatment paradigm, which also includes ocriplasmin 
or ocriplasmin followed by vitrectomy. The model assumes costs are all-inclusive 
over a 1-year period and accounts for diagnosis and monitoring, vitrectomy, intra-
vitreal injection procedures, pharmacy, and treatment of complications. Costs were 
obtained from 2012 Medicare fee-for-service rates and Medicare claims using the 
2005-2009 Outpatient and Part B 5% Standard Analytical Files. Results: Based on 
an aggregate market penetration of 23% (replacing 44% of vitrectomy patients and 
2.5% of clinical management patients), ocriplasmin reduces total vitrectomies by 
35%, resulting in cost savings of $27,884 per year to a 1 million-member health plan. 
Major cost impact drivers include cost of vitrectomy and associated complications, 
cost of ocriplasmin and complications, and percent of ocriplasmin patients requir-
ing vitrectomy. ConClusions: In addition to reducing surgical complications and 
improving patient quality of life, ocriplasmin has the potential to reduce direct 
medical costs to a managed care plan for treating sVMA.
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objeCtives: Identify the real world treatment patterns, medical history, resource 
use and costs of patients with choroidal neovascularization (CNV) secondary to 
pathologic myopia (PM), or myopic CNV (mCNV), in Canada. Methods: Ninety-
eight (98) patients with mCNV from 16 centres across Canada were included in this 
retrospective study. Medical records covering at least one year and up to two years 
of follow up data from the CNV diagnosis were analyzed to gather all information 
related to mCNV. Results: Patients had a mean age of 55.0 years (range: 22 - 82 
years) at the time of their first lifetime CNV episode. Baseline characteristics of 
patients showed that 71.4% of participants were female, 57.1% and 28.6% had sub-
foveal or juxtafoveal CNV in the affected eye, respectively. The bilaterality of mCNV 
was 13.3%. The approximate mean Snellen score at the time of CNV diagnosis was 
20/125 in the affected eye and 20/80 in the fellow eye. Forty-nine percent (49%) of 
patients had visual acuity (VA) severity in the affected eye of normal/mild vision 
loss (VA 20/20 to > 20/80), 19% moderate vision loss (VA 20/80 to > 20/200), and 32% 
severe vision loss/nearly blind (VA ≤ 20/200). The mean duration of CNV episode was 
0.78 years. Almost 90% of mCNV patients consulted a Retina Specialist (on average 
6.0 times/year), 11.2% of patients had to visit the ER and 2.0% were admitted to 
hospital due to mCNV. Most patients were treated with an anti-VEGF therapy and 
received on average 3.8 injections per year. The annual average myopic CNV-related 
cost per patient was $3,433. The cost was $2,964, $3,595 and $4,060 for patients with 
mild, moderate and severe vision loss, respectively. ConClusions: This is the first 
this study, 211 patients with mCNV were matched for demographic characteristics 
with 211 PM controls. Results: The prevalence of CNV secondary to PM was esti-
mated to be 0.084% in the general adult population with an annual incidence of 
0.0061%. Amongst PM patients, 6.2% develop CNV. The bilaterality of mCNV was 10%. 
CNV was mostly subfoveal (87%) and was more common in women than men. At the 
time of CNV diagnosis, the mean Snellen score was 20/100 in the affected eye. The 
most common treatments were verteporfin and laser photocoagulation. The burden 
of resource use, including hospitalizations and emergency, general practitioners 
clinic and ophthalmology visits, is more important in mCNV patients than in PM 
patients (p< 0.01). ConClusions: In a Canadian real-world setting, the prevalence 
and the annual incidence of myopic CNV was 0.084% and 0.0061%, respectively. This 
is the first Canadian study investigating the epidemiology of myopic CNV and the 
results will help us better understand this debilitating disease.
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objeCtives: Few data on the epidemiology and costs of vitreomacular traction 
(VMT) in France are available. Therefore, a study was conducted to evaluate the 
management and associated costs of the most severe forms of this condition, 
which are treated by vitrectomy. Methods: A retrospective, observational study 
was conducted using the French hospital discharge database (PMSI) by identify-
ing all patients having undergone a vitrectomy in 2009 for VMT, with or without 
a macular hole. There was a follow-up period of 2 years. Medical records were 
analyzed by health informatics doctors from 4 hospitals in order to establish an 
extraction algorithm for the relevant patient stays, in the absence of formal VMT 
codes. Patient characteristics, length of stay, rehospitalization for an ophthalmic 
reason, and hospital charges were described. Results: In 2009, 3,463 patients 
were hospitalized for a first-time vitrectomy related to VMT. The mean age was 
68.9 years, with 59% being women. The initial length of stay was primarily 2 to 3 
days (respectively for 21% and 55% of patients, mean of 2.8). Approximately 11% 
of patients underwent concomitant cataract surgery. During the 2-year follow-up, 
48.6% of patients were rehospitalized for an ophthalmic reason, mainly for cata-
ract surgery (75.7%) or retinal tear and/or detachment (14.8%), with an average stay 
of 3 days. The mean charge for the initial stay was € 2,697 and the mean charge for 
rehospitalization for ophthalmic reasons was € 2,930 per stay. ConClusions: This 
study is the first providing extensive data on epidemiology and hospital journeys 
for patients suffering from VMT and treated by vitrectomy in France. Our study 
shows that there is a high rate of rehospitalization for ophthalmic causes at 2 
years post-vitrectomy, and the economic impact is sizeable. Early treatment of 
VMT could reduce the need for surgery and the complications of advanced forms 
of this condition.
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objeCtives: Describe the epidemiological characteristics and treatments for 
chronic plaque psoriasis in a large, Canadian, real-world dataset. Methods: This 
was an observational, retrospective cohort of patients ≥ 18 years who, between 
2008 and 2012 received a diagnosis of psoriasis (overall, scalp, nail, chronic 
plaque, pustular, palmoplantar pustulosis and guttate psoriasis) identified 
by ICD9-10 and/or text coding, and who were prescribed at least 1 treatment. 
Data were retrieved from the Southwestern Ontario (SWO) database, which is 
a representative primary care, researchable database of over 325,000 unique 
patient records in Ontario, Canada. Results: Among 325,618 patients in the 
SWO database, 7,935 patients had a diagnosis of psoriasis between January 1, 
2008 and December 31, 2012 (prevalence 2.44%). Of these, 98% (n=7,776) were 
treated. Chronic plaque psoriasis was the most common subtype of psoriasis 
(85%, n=6,610), followed by scalp psoriasis (50%, n=3,888) in patients receiving 
treatment. Among chronic plaque psoriasis patients, duration of disease ranged 
from 1 to 23 years. Mean age at diagnosis was 31 (sd=12) years. Patients with mild 
disease were generally treated with topicals, most commonly corticosteroids 
(65%), salicylic acid (28%) and/or coal tar (19%). Phototherapy (NB-UVB, 
psoralen+UVA) and oral systemic agents (acitretin, cyclosporine, methotrexate) 
were also prescribed. Twenty eight percent (28%) of chronic plaque psoriasis 
patients had a moderate to severe condition. About 60% of moderate to severe 
patients were treated with phototherapy, whereas 33% were prescribed biologics 
(adalimumab, etanercept, infliximab, ustekinumab). ConClusions: Psoriasis 
is a significant problem in primary care, affecting over 2% of the population. 
Of these, 85% have chronic plaque psoriasis and 28% are considered moderate 
to severe. Results of this study confirm those observed in the literature. This 
real-world database may be used as a resource for further examination of the 
effectiveness of psoriasis treatment and health resource use.
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objeCtives: Fradiomycin sulfate - methylprednisolone combination ointment (F/M) 
is an anti-inflammatory topical drug indicated for ophthalmologic or otorhinolaryn-
